Unlocking the influence of PNPLA3 mutations on lipolysis: Insights into lipid droplet formation and metabolic dynamics in metabolic dysfunction-associated steatotic liver disease

Biochimica et Biophysica Acta (BBA) - General Subjects, Journal Year: 2025, Volume and Issue: unknown, P. 130766 - 130766

Published: Jan. 1, 2025

Language: Английский

---

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(1), P. 498 - 498

Published: Jan. 2, 2022

Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, and enlargement of the diameter hepatocytes (ballooning hepatocytes), with or without fibrosis. It affects 20% patients non-alcoholic fatty liver disease (NAFLD). Due to dysfunction numerous metabolic changes that commonly accompany condition (obesity, insulin resistance, type 2 diabetes, syndrome), secretion organokines modified, which may contribute pathogenesis progression disease. In this sense, study aimed perform a review role in NASH. Thus, combining descriptors such as NASH, organokines, oxidative stress, dyslipidemia, search was carried out EMBASE, MEDLINE-PubMed, Cochrane databases articles published last ten years. Insulin inflammation mitochondrial dysfunction, fructose, intestinal microbiota were factors identified participating genesis Changes pattern (adipokines, myokines, hepatokines, osteokines) directly indirectly aggravating compromise homeostasis. further studies involving skeletal muscle, adipose, bone, tissue endocrine organs are essential better understand modulation involved NASH advance treatment

Language: Английский

---

Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study

Open Forum Infectious Diseases, Journal Year: 2022, Volume and Issue: 9(4)

Published: Feb. 9, 2022

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is the most common associated with systemic changes in immune response, which might be coronavirus 2019 (COVID-19) severity. The aim of this study was to investigate impact NAFLD on COVID-19 severity and outcomes. Methods A prospective observational included consecutively hospitalized adult patients, between March June 2021, severe COVID-19. Patients were screened for by ultrasound subsequently diagnosed NAFLD. daily followed until discharge, demographic, clinical, laboratory data collected correlated clinical Results Of 216 patients included, 120 (55.5%) had group higher C-reactive protein (interquartile range [IQR]) (84.7 [38.6–129.8] mg/L vs 66.9 [32.2–97.3] mg/L; P = .0340), interleukin-6 (49.19 [22.66–92.04] ng/L 13.22 [5.29–39.75] ng/L; < .0001), aspartate aminotransferase (58 [40–81] IU/L 46 [29–82] IU/L; .0123), alanine (51 [32–73] 40 [23–69] .0345), lactate dehydrogenase (391 [285–483] 324 [247–411] .0027). assessed 7-category ordinal scale, more frequently required high-flow nasal cannula or noninvasive ventilation (26, 21.66%, 10, 10.42%; .0289), longer duration hospitalization (IQR) (10 [8–15] days 9 [6–12] days; .0018), pulmonary thromboembolism (26.66% 13.54%; .0191). On multivariable analyses, negatively time recovery (hazard ratio, 0.64; 95% CI, 0.48 0.86) identified as a risk factor thrombosis (odds 2.15; 1.04 4.46). Conclusions severity, adverse outcomes, frequent thrombosis.

Language: Английский

---

Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 244, P. 108372 - 108372

Published: March 7, 2023

Language: Английский

---

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study

Medicina, Journal Year: 2023, Volume and Issue: 59(11), P. 1935 - 1935

Published: Nov. 1, 2023

Background and Objectives: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn's (CD) ulcerative colitis (UC). One of the extraintestinal manifestations IBD nonalcoholic fatty liver (NAFLD). NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination most commonly used imaging method for diagnosis NAFLD. This cross-sectional observational retrospective study aimed to evaluate US prevalence in patients their clinical features. Materials Methods: A total 143 with underwent hepatic were divided into different groups according presence or absence Subsequently, new exclusion criteria dysmetabolic comorbidities (defined as plus) applied. Results: The was 23% (21% CD 24% UC, respectively). Most IBD-NAFLD male older showed significantly higher values body mass index, waist circumference, duration, age at onset than those without percentage stenosing phenotype left-side colitis. Regarding metabolic features, hypertension plus criteria. Also, alanine aminotransferase triglycerides lower levels high-density lipoproteins are reported these patients. Conclusions: suggest performing screening subjects affected detect earlier. present several that would fall within definition metabolic-associated disease. Finally, we encourage larger longitudinal studies, including healthy controls, provide further confirmation our preliminary data.

Language: Английский

---

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions

Clinical Diabetes and Endocrinology, Journal Year: 2024, Volume and Issue: 10(1)

Published: Dec. 2, 2024

Language: Английский

---

Antidiabetic Properties of Chitosan and Its Derivatives

Marine Drugs, Journal Year: 2022, Volume and Issue: 20(12), P. 784 - 784

Published: Dec. 17, 2022

Diabetes mellitus is a chronic metabolic disorder. In addition to taking medication, adjusting the composition of diet also considered one effective methods control levels blood glucose. Chitosan and its derivatives are natural versatile biomaterials with health benefits. has potential alleviate diabetic hyperglycemia by reducing hepatic gluconeogenesis increasing skeletal muscle glucose uptake utility. Scientists focus on glucose-lowering effect chitosan oligosaccharide (COS). COS supplementation abnormal metabolism in rats inhibiting lipid peroxidation liver. Both high low molecular weight feeding reduced insulin resistance accumulation liver adipose tissue ameliorating inflammation rats. can reduce but less ability lipids A clinical trial showed that 3-month administration increased sensitivity decreased body triglycerides obese patients. Generally Recognized as Safe; however, they still be safety concerns. This review highlights recent advances glucose-lowering/antidiabetic effects safety.

Language: Английский

---

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: Feb. 14, 2024

Introduction A prognostic model to predict liver severity in people with metabolic dysfunction-associated steatotic disease (MASLD) is very important, but the accuracy of most commonly used tools not yet well established. Objective The meta-analysis aimed assess different serological biomarkers predicting fibrosis MASLD. Methods Adults ≥18 years age MASLD were included, following: biopsy and aspartate aminotransferase-to-platelet ratio (APRI), index-4 (FIB-4), non-alcoholic fatty score (NFS), body mass index, aminotransferase/alanine aminotransferase ratio, diabetes (BARD score), FibroMeter, FibroTest, enhanced (ELF), Forns score, Hepascore. Meta-analyses performed using a random effects based on DerSimonian Laird methods. study’s risk bias was assessed Quality Assessment Diagnostic Accuracy Studies-2. Results In total, 138 articles which 86 studies 46,514 participants met criteria for meta-analysis. results summary area under receiver operating characteristic (sAUROC) curve, according models, as follows: APRI: advanced (AF): 0.78, any (AnF): 0.76, significant (SF): cirrhosis: 0.72; FIB-4: 0.83, AF: 0.81, AnF: 0.77, SF: 0.75; NFS: 0.71, 0.69; BARD score: 0.73; FibroMeter: 0.88, 0.84; FibroTest: 0.86, 0.78; ELF: 0.87. Conclusion this suggest that, when comparing scores biopsies, following models showed better diagnostic MASLD: FIB-4 fibrosis, FibroMeter ELF cirrhosis. Clinical trial registration: [ https://clinicaltrials.gov/ ], identifier [CRD 42020180525].

Language: Английский

---

Nonalcoholic fatty liver disease from a primary care perspective

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 25(6), P. 1421 - 1433

Published: Feb. 15, 2023

Nonalcoholic fatty liver disease (NAFLD) affects up to one-third of the US population. Approximately one-fifth patients with NAFLD have nonalcoholic steatohepatitis (NASH), characterized by hepatocyte damage and inflammation or without fibrosis. NASH leads greater risk liver-related complications mortality, poorest outcomes seen in advanced is also associated other metabolic comorbidities conveys an increased adverse cardiovascular extrahepatic cancers. Despite its high prevalence, frequently underdiagnosed. This a significant concern, given that early diagnosis key step preventing progression NASH. In this review, we describe clinical impact from perspective both clinician patient. addition, provide practical guidance on management for primary care providers, who play pivotal role frontline NASH, use case studies illustrate real-world scenarios encountered setting.

Language: Английский

---

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2024, Volume and Issue: Volume 17, P. 545 - 561

Published: Feb. 1, 2024

Background: Non-alcoholic fatty liver disease (NAFLD) is a common and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD. Methods: The terms "Non-alcoholic Fatty Liver Disease" "NAFLD" were used search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, Phase IV, completed eligible for this review. Results: database was searched examining pharmacotherapeutics revealed 1364 trials, with 31 meeting inclusion Out these, 19 finalized evaluation. dominant intervention model Parallel. most prevalent studies Korea (26.3%) China (21.1%). metformin (12.1%), others like Exenatide Pioglitazone accounting 9.1%. Conclusion: Therapeutics manage are limited. However, various medications offer potential benefits. Further investigations definitely warranted. Keywords: NAFLD, hepatology, clinical therapeutics, metabolic disorder

Language: Английский

---